Skip to main content
Top
Published in: Journal of Translational Medicine 1/2015

Open Access 01-12-2015 | Research

The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study

Authors: Elena Raffetti, Francesco Donato, Filippo Castelnuovo, Nicoletta Ladisa, Giuseppe Paraninfo, Elisa Di Filippo, Daniela Segala, Giuliana Cologni, Alessandra Bandera, Fabio Zacchi, Simona Digiambenedetto, Massimo Di Pietro, Francesco Castelli, Eugenia Quiros-Roldan, MASTER Cohort

Published in: Journal of Translational Medicine | Issue 1/2015

Login to get access

Abstract

Background

The systemic inflammatory response has been postulated as having prognostic significance in a wide range of different cancer types. We aimed to assess the prognostic role of inflammatory markers on survival in HIV-infected patients with Non-Hodgkin Lymphoma (NHL), and to compute a prognostic score based on inflammatory biomarkers.

Methods

We evaluated data on HIV patients with NLH diagnosis between 1998 and 2012 in a HIV Italian Cohort. Using Cox proportional regression model, we assessed the prognostic role of Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR), Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS), Prognostic Index (PI), and Prognostic Nutritional Index (PNI). We also computed a risk score equation, assigning patients to a derivation and a validation sample. The area under the curve (AUC) was use to evaluate the predictive ability of this score.

Results

215 non-Hodgkin lymphoma cases (80.0% males) with a mean age of 43.2 years were included. Deaths were observed in 98 (45.6%) patients during a median follow up of 5 years. GPS, mGPS, PI and PNI were independently associated with risk of death. We also computed a mortality risk score which included PNI and occurrence of an AIDS event within six months from NHL diagnosis. The AUCs were 0.69 (95% CI 0.58 to 0.81) and 0.69 (95% CI 0.57 to 0.81) at 3 and 5 years of the follow-up, respectively.

Conclusions

GPS, mGPS, PI and PNI are independent prognostic factors for survival of HIV patients with NHL.
Literature
1.
go back to reference Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, et al. Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an Italian multicenter study. PLoS One. 2014;23:9(4). Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, et al. Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an Italian multicenter study. PLoS One. 2014;23:9(4).
2.
go back to reference Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96(8):2730–4.PubMed Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96(8):2730–4.PubMed
3.
go back to reference Robotin MC, Law MG, Milliken S, Goldstein D, Garsia RJ, Dolan GM, et al. Clinical features and predictors of survival of AIDS-related non-Hodgkin’s lymphoma in a population-based case series in Sydney, Australia. HIV Med. 2004;5(5):377–84.CrossRefPubMed Robotin MC, Law MG, Milliken S, Goldstein D, Garsia RJ, Dolan GM, et al. Clinical features and predictors of survival of AIDS-related non-Hodgkin’s lymphoma in a population-based case series in Sydney, Australia. HIV Med. 2004;5(5):377–84.CrossRefPubMed
4.
go back to reference Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, et al. A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy. Ann Intern Med. 2005;143(4):265–73.CrossRefPubMed Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, et al. A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy. Ann Intern Med. 2005;143(4):265–73.CrossRefPubMed
5.
go back to reference Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro Murillo AM, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009;23(15):2029–37.CrossRefPubMed Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro Murillo AM, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009;23(15):2029–37.CrossRefPubMed
6.
go back to reference Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med 2014 Sep 23. Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med 2014 Sep 23.
7.
go back to reference Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol. 2005;23(33):8477–82.CrossRefPubMed Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol. 2005;23(33):8477–82.CrossRefPubMed
8.
go back to reference Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Tellez MJ, et al. Prognosis of AIDS-Related Systemic Non-Hodgkin Lymphoma Treated With Chemotherapy and Highly Active Antiretroviral Therapy Depends Exclusively on Tumor-Related Factors. JAIDS. 2007;44(2):167–73.PubMed Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Tellez MJ, et al. Prognosis of AIDS-Related Systemic Non-Hodgkin Lymphoma Treated With Chemotherapy and Highly Active Antiretroviral Therapy Depends Exclusively on Tumor-Related Factors. JAIDS. 2007;44(2):167–73.PubMed
9.
go back to reference Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23(19):4430–8.CrossRefPubMed Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23(19):4430–8.CrossRefPubMed
10.
go back to reference A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329(14):987–94. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329(14):987–94.
12.
go back to reference Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–63.CrossRefPubMed Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–63.CrossRefPubMed
13.
go back to reference McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.CrossRefPubMed McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.CrossRefPubMed
14.
go back to reference Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218–30.CrossRefPubMed Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218–30.CrossRefPubMed
15.
go back to reference Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.CrossRefPubMed Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.CrossRefPubMed
16.
go back to reference Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537–49.CrossRefPubMed Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537–49.CrossRefPubMed
17.
go back to reference Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015;94(1):57–63.CrossRefPubMed Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015;94(1):57–63.CrossRefPubMed
18.
go back to reference Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, et al. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer. 2014;110(2):369–74.PubMedCentralCrossRefPubMed Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, et al. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer. 2014;110(2):369–74.PubMedCentralCrossRefPubMed
19.
go back to reference Li YJ, Jiang WQ, Huang JJ, Xia ZJ, Huang HQ, Li ZM. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol. 2013;88(5):394–9.CrossRefPubMed Li YJ, Jiang WQ, Huang JJ, Xia ZJ, Huang HQ, Li ZM. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol. 2013;88(5):394–9.CrossRefPubMed
20.
go back to reference Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–95.CrossRefPubMed Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–95.CrossRefPubMed
21.
go back to reference Harrell F. General Aspects of Fitting Regression Models. In: Regression Modeling Strategies - With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer-Verlag; 2011. p. 23–4. Harrell F. General Aspects of Fitting Regression Models. In: Regression Modeling Strategies - With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer-Verlag; 2011. p. 23–4.
22.
go back to reference Akaike H. A New Look at the Statistical Model Identification. IEEE Trans Autom Control. 1974;AC-19(6):716–23.CrossRef Akaike H. A New Look at the Statistical Model Identification. IEEE Trans Autom Control. 1974;AC-19(6):716–23.CrossRef
23.
go back to reference Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefPubMed Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefPubMed
24.
go back to reference Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.CrossRefPubMed Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.CrossRefPubMed
25.
go back to reference Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther. 2007;12(6):931–9.PubMed Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther. 2007;12(6):931–9.PubMed
26.
go back to reference Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010;24(11):1765–70.PubMedCentralCrossRefPubMed Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010;24(11):1765–70.PubMedCentralCrossRefPubMed
27.
go back to reference Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–62.PubMedCentralCrossRefPubMed Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–62.PubMedCentralCrossRefPubMed
28.
go back to reference Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105(16):1221–9.PubMedCentralCrossRefPubMed Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105(16):1221–9.PubMedCentralCrossRefPubMed
29.
go back to reference Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, et al. A new prognostic score for AIDS-related lymphomas in the Rituximab-era. Haematologica. 2014;123(6):837–42. Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, et al. A new prognostic score for AIDS-related lymphomas in the Rituximab-era. Haematologica. 2014;123(6):837–42.
30.
go back to reference Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with aids-related non-Hodgkin’s lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2001;41:105–16.CrossRefPubMed Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with aids-related non-Hodgkin’s lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2001;41:105–16.CrossRefPubMed
Metadata
Title
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study
Authors
Elena Raffetti
Francesco Donato
Filippo Castelnuovo
Nicoletta Ladisa
Giuseppe Paraninfo
Elisa Di Filippo
Daniela Segala
Giuliana Cologni
Alessandra Bandera
Fabio Zacchi
Simona Digiambenedetto
Massimo Di Pietro
Francesco Castelli
Eugenia Quiros-Roldan
MASTER Cohort
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-015-0446-8

Other articles of this Issue 1/2015

Journal of Translational Medicine 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine